LIXT - Lixte Biotechnology Holdings, Inc. Price-to-Projected Revenue Ratio

The future P/S of the business allows for an assessment of the investment potential of Lixte Biotechnology (LIXT), where captures the value of this parameter. Price action relies on the efficacy of combined therapy with phosphatase inhibitors. The company is currently scaling clinical trials in collaboration with oncology centers to capitalize on its patents. Revenue is expected to be generated through licensing agreements and royalties from global pharmaceutical behemoths.

Lixte Biotechnology Holdings Inc. - LIXT Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Lixte Biotechnology, Inc. (LIXT)

- market price and analyst price targets:

Price Chart Lixte Biotechnology Holdings, Inc.|LIXT - Price Target Chart

- market capitalization statistics:

Market Value Lixte Biotechnology, Inc.|LIXT - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Lixte Biotechnology|LIXT - Book Value of Business|Market Cap to Net Assets Ratio lixte.com|LIXT - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Lixte Biotechnology|LIXT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Lixte Biotechnology|LIXT - Company Cumulative Indebtedness|Debts to Book Capitalization Lixte Biotechnology, Inc.|LIXT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Lixte Biotechnology|Quick Liquidity lixte.com

- financial results and valuation multiples details:

LIXT - Final Profit|Projected Future Earnings Lixte Biotechnology|LIXT - P/E Multiple|Future Price to Earnings Lixte Biotechnology Holdings|LIXT - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Lixte Biotechnology, Inc.|LIXT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Lixte Biotechnology|LIXT - Earnings per share for the last twelve months|Quarterly EPS earnings growth lixte.com|LIXT - Expected net earnings per share growth this year|Expected earnings per share growth for next year Lixte Biotechnology

- revenue and sales proceeds data:

LIXT - Company Sales Volume|Company Future Sales Volume Lixte Biotechnology Holdings, Inc.|LIXT - Market Cap to Sales Volume|Forward P/S Multiple Lixte Biotechnology, Inc.

General company analysis:Lixte Biotechnology Holdings, Inc. LIXT

Lixte Biotechnology develops inhibitors for cancer therapy, relying on patent protection for compounds at the preclinical stage. By analyzing the forward P/S multiple, an investor determines the market value of one dollar of projected revenue, which allows for a comparison of current quotes with expected demand and an assessment of the business's fair value relative to its long-term potential and risks.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Projected Revenue Ratio Cellectar Biosciences|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|Cyclacel (CYCC) - Price-to-Projected Revenue Ratio|GTHX (G1 Therapeutics) - Price-to-Projected Revenue Ratio|KRON (Kronos Bio Corp) - Forward P/S Multiple|Kintara Pharma (KTRA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ONCT (Oncternal Therapeutics)|portagebiotech.com - Market Cap to Projected Revenue